Cardiff Oncology: Pay

Cardiff Oncology paid its 3 named executives $6.8M in total in FY2025 (Dec). CEO Mark Erlander was paid $3.0M of that.

Pay$100 in the stock at the end of FY21 → $47
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Mark ErlanderCEO
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Roger Sidhu, CMO
FY2025 (Dec)
1 year
James LevineCFO
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 2 peers with pay on file was $6.1M. CEO pay of Cardiff Oncology for that year is not on file.

  1. 1Corvus Pharmaceuticals
  2. 2Compass Therapeutics
  3. 3Cardiff OncologyNot disclosed
  4. 4ALX Oncology Holdings, Inc.Not disclosed
  5. 5Acrivon Therapeutics, Inc.Not disclosed
  6. 6Actinium Pharmaceuticals, Inc.Not disclosed
  7. 7BioAtla, Inc.Not disclosed
  8. 8Black Diamond Therapeutics, Inc.Not disclosed
  9. 9Candel TherapeuticsNot disclosed
  10. 10Curis, Inc.Not disclosed
  11. 11Elevation Oncology, Inc.Not disclosed
  12. 12Immix Biopharma, Inc.Not disclosed
  13. 13Kezar Life Sciences, Inc.Not disclosed
  14. 14Kronos Bio, Inc.Not disclosed
  15. 15Lantern Pharma, Inc.Not disclosed
  16. 16Leap Therapeutics, Inc.Not disclosed
  17. 17Pyxis Oncology, Inc.Not disclosed
  18. 18Syros Pharmaceuticals, Inc.Not disclosed
  19. 19Tempest Therapeutics, Inc.Not disclosed
  20. 20Viracta Therapeutics, Inc.Not disclosed
  21. 21Werewolf Therapeutics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.